住宅房產ETF-iShares REZ 深 滬
已收盤 09-05 16:00:00 美东时间
85.11
+0.860
+1.02%
華盛通- 最 高85.31
- 今 開84.66
- 成交量 3.50万股
- 最 低 84.40
- 昨 收 84.25
- 總市值 8.17亿
- 52周最高 89.6228
- 市盈率 靜 --
- 換手率 0.36%
- 52周最低 72.7112
- 委 比 0.00%
- 總股本 960.00万
- 歷史最高 93.1693
- 量 比 1.11
- 振 幅 1.08%
- 歷史最低 27.343
- 每 手 1
- 風險率 2.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多What's Going On With Nektar Therapeutics Stock On Thursday?
Nektar Therapeutics stock is trading higher with no news, possibly due to Sanofi's disappointing results.
09-05 02:52
Rezolute to Participate in Upcoming Investor Conferences
Rezolute, Inc. announced that its management will participate in three upcoming investor conferences in September 2025: the Cantor Global Healthcare Conference (September 3-5), the H.C. Wainwright 27th Annual Global Investment Conference (September 8-10), and the Morgan Stanley 23rd Annual Global Healthcare Conference (September 8-10). Management will engage in Fireside Chats and one-on-one investor meetings at these events. The Company focuses o...
08-27 11:30
Home sales falling through at highest rate in years - Redfin
Home purchases are getting canceled at the highest rate in years as high prices, elevated mortgage rates and economic uncertainty deter buyers, according to Redfin's analysis of MLS pending-sales data...
08-25 17:17
Somnigroup International's CorMedix to Acquire Melinta in $300M Deal, Expanding Infectious Disease Portfolio
CorMedix Inc. ("CorMedix") (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, and Melinta Therapeutics LLC ("Melinta"),
08-07 19:14
Nektar Therapeutics launches proposed public offering
Nektar Therapeutics (NASDAQ:NKTR) has commenced an underwritten public offering of shares of its common stock and pre-funded warrants to purchase shares of its common stock. NKTR -2.45% after hours to...
07-01 04:10
Nektar Therapeutics Announces Proposed Public Offering
SAN FRANCISCO, June 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of imm...
07-01 04:02
Nektar Therapeutics surge continues as stock up another 25%
Nektar Therapeutics (NASDAQ:NKTR), which closed Tuesday up ~156% after its lead asset, rezpegaldesleukin, met its main goal in a mid-stage trial for atopic dermatitis, also known as eczema, is up anot...
06-26 02:14
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?
Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.
06-26 01:42
美股异动 | Nektar Therapeutics(NKTR.US)大涨近30% 湿疹治疗药物临床研究取得超预期积极结果
周三，Nektar Therapeutics(NKTR.US)大涨近30%，报31.70美元。
06-25 22:25
创新药重磅消息! “T细胞黑马”Nektar(NKTR.US)湿疹疗效炸裂 股价单日暴涨150%
Nektar Therapeutics股价在美股盘中一度暴涨超180%，截至当日美股收盘收涨156%至24.450美元。
06-25 11:54
